litigation Archives -

Elizabeth Holmes, the founder and former chief executive of blood testing biotech Theranos, has been sentenced after being

Ex-Theranos CEO Elizabeth Holmes sentenced to 11 years

https://pharmaphorum.com/news/ex-theranos-ceo-elizabeth-holmes-jailed-for-11-years/

News/ News/ News/ Patients/ Sales and Marketing

Walmart offers $3.1bn to settle opioid epidemic lawsuits

Phil Taylor litigation, opioid crisis, pharmacy, Walmart 0 Comment

Walmart has become the latest big pharmacy chain in the US to put forward a settlement to resolve

Walmart offers $3.1bn to settle opioid epidemic lawsuits

https://pharmaphorum.com/news/walmart-offers-3-1bn-to-settle-opioid-epidemic-lawsuits/

News/ News/ R&D

Stanford prof pays investors in defunct biotech Nuredis $29m

Phil Taylor Biotech, Huntington's disease, investment, litigation, Nuredis 0 Comment

A prominent genetics professor at Stanford University in the US has paid $29 million to investors in Nuredis

Stanford prof pays investors in defunct biotech Nuredis $29m

https://pharmaphorum.com/news/stanford-prof-pays-investors-in-defunct-biotech-nuredis-29m/

A lot of empty plastic blister packaging of pharmaceutical tablets and pills on blue background. Concept of end of treatment, the lack of medicines in the pharmacy or the impossibility to get them

News/ News/ News/ Patients/ Sales and Marketing

Pharmacy chains agree $10bn settlement in opioid litigation

Phil Taylor CVS Health, litigation, opioid crisis, Walgreens, Walmart 0 Comment

CVS Health and Walgreens have become the first two US pharmacy chains to agree a settlement worth nearly

Pharmacy chains agree $10bn settlement in opioid litigation

https://pharmaphorum.com/news/pharmacy-chains-agree-10bn-settlement-in-opioid-litigation/

News/ News/ Sales and Marketing

Novartis facing Gilenya generics again as Supreme Court lifts stay

Phil Taylor drug patents, generic, Gilenya, HEC Pharma, litigation, Novartis, Sales and Marketing 0 Comment

Novartis’ hopes that the Supreme Court would protect its big-selling multiple sclerosis drug Gilenya from generic competition have

Novartis facing Gilenya generics again as Supreme Court lifts stay

https://pharmaphorum.com/news/novartis-facing-gilenya-generics-again-as-supreme-court-lifts-stay/

News/ News/ Sales and Marketing

Supreme court throws Novartis a lifeline for Gilenya defense

Phil Taylor generic, Gilenya, HEC Pharma, litigation, multiple sclerosis, Novartis, patent, patent litigation 0 Comment

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral

Supreme court throws Novartis a lifeline for Gilenya defense

https://pharmaphorum.com/news/supreme-court-throws-novartis-a-lifeline-for-gilenya-defense/

News/ News/ Sales and Marketing

Whistleblower gets $250m as Biogen settles US kickbacks case

Phil Taylor Avonex, Biogen, litigation, multiple sclerosis, Tecfidera, Tysabri, US 0 Comment

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to

Whistleblower gets $250m as Biogen settles US kickbacks case

https://pharmaphorum.com/news/whistleblower-gets-250m-as-biogen-settles-us-kickbacks-case/

News/ News/ Sales and Marketing

Astellas facing generics to big-selling Lexiscan product in US

Phil Taylor Amphastar, Astellas, generic, Glenmark, Hospira, Lexiscan, litigation, patent litigation 0 Comment

Astellas has won a reprieve in its attempt to stop Pfizer’s generic medicines unit Hospira launching a copycat

Astellas facing generics to big-selling Lexiscan product in US

https://pharmaphorum.com/news/astellas-facing-generics-to-big-selling-lexiscan-product-in-us/

News/ News/ Sales and Marketing

Novartis knocked back again in bid to block Gilenya generics in US

Phil Taylor Gilenya, HEC Pharma, litigation, multiple sclerosis, Novartis, patent 0 Comment

Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early

Novartis knocked back again in bid to block Gilenya generics in US

https://pharmaphorum.com/news/novartis-knocked-back-again-in-bid-to-block-gilenya-generics-in-us/

Trending

litigation

Login